Although aberrant methylation of CCDC181 was found in lung and prostate cancer in previous studies and in endometrial cancer in Taiwanese cohort, aberrant methylation of CCDC181 was a good cancer biomarker with high sensitivity (81.5%) in breast cancer. This evidence concerns the gene CCDC181 and breast cancer.